Listed

XBiotech Inc.: Form 10-K for the period ended Dec 31, 2017

Filed with the SEC on Mar 16, 2018 and accepted by EDGAR at Mar 16, 2018, 16:15 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2017-01-01 to 2017-12-31$26.4mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2017-10-01 to 2017-12-31−$7.5mus-gaap:OperatingIncomeLoss
Operating income12 months2017-01-01 to 2017-12-31−$34.1mus-gaap:OperatingIncomeLoss
Income tax12 months2017-01-01 to 2017-12-31$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2017-10-01 to 2017-12-31−$7.2mus-gaap:NetIncomeLoss
Net income12 months2017-01-01 to 2017-12-31−$33.1mus-gaap:NetIncomeLoss
Diluted EPS3 months2017-10-01 to 2017-12-31−$0.20us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2017-01-01 to 2017-12-31−$33.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2017-01-01 to 2017-12-31$1.4mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2017-12-31$31.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-12-31$33.3mus-gaap:AssetsCurrent
Total assetsAt period end2017-12-31$63.0mus-gaap:Assets
Current liabilitiesAt period end2017-12-31$2.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-12-31$2.8mus-gaap:Liabilities
Shareholders' equityAt period end2017-12-31$60.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001171843-18-002043. Last ingested by Listed: Nov 14, 2026, 18:14 ET. Listed shows no prices and gives no investment advice.